



REQUEST FOR PROPOSAL – *Landscape analysis and review of country decision-making for vaccines*

INTRODUCTION

The Wellcome Trust is the world's second highest-spending charitable foundation, and a unique scientific and cultural institution of global significance, scale and achievement. Dedicated to improving human and animal health, over the next five years Wellcome aims to spend up to £5 billion in support for outstanding researchers in health research, humanities and social science, as well as education, public engagement and application of research to medicine. Further information about Wellcome can be found at www.wellcome.ac.uk and all prospective suppliers are encouraged to visit the website to gain an insight into Wellcome's diverse activities.

OBJECTIVES OF THE CONSULTANCY

Wellcome recognises the importance of ensuring that countries have the expertise and evidence they need to make timely decisions on vaccine introduction and programmatic implementation. This will maximize the benefits of investments in new vaccine development and will ensure that evidence generated can be utilised for maximal impact. Wellcome is working with partners to develop a strategy to support sustainable country decision-making for vaccines. To this end, Wellcome is requesting proposals for a landscape analysis and review of approaches to country decision-making for vaccines. The analysis will likely include a brief systematic review and landscape analysis, a review of various approaches to country decision-making for vaccines, and case studies of countries using evidence-informed decision-making for vaccines and the relative strengths and weaknesses of these approaches.

RESPONSE FORMAT

Structure of the Response

Please complete your Proposal according to the template in Appendix 3, addressing the Objectives and Scope of Work found in Appendix 1.

Proposed Costs

Proposals must include a detailed breakdown of proposed costs and state if they do or do not include VAT or any other levies. Prospective suppliers should note that Wellcome's standard payment terms are 20 business days in arrears from receipt of a valid invoice and evidence of completion of the work requested.

Response Timetable

11 February 2019	Issue of Request for Proposal (RfP)
25 February 2019	Submission of Proposals
4 March 2019	Initial Response from Wellcome



Submission of Proposal

Your proposal should be submitted by email to k.cook@wellcome.ac.uk by **11:59pm (GMT) on 25th February 2018**.

We encourage any parties intending to submit a proposal to have an initial discussion regarding the project. Any queries regarding this RfP should be directed to Kori Cook, who can be contacted by email at k.cook@wellcome.ac.uk.

Independent Proposal

By submission of a proposal, prospective suppliers warrant that the prices in the proposal have been arrived at independently, without consultation, communication, agreement or understanding for the purpose of restricting competition, as to any matter relating to such prices, with any other potential supplier or with any competitor.

Costs Incurred by Prospective Suppliers

It should be noted that this document relates to a Request for Proposal only and not a firm commitment from the Trust to enter into a contractual agreement. In addition the Trust will not be held responsible for any costs associated with the production of a response to this Request for Proposal.

Enclosed

Appendix 1 – Specification

Appendix 2 – Wellcome General Terms and Conditions

Appendix 3 – Response template



Appendix 1 – Specification

BACKGROUND

In addition to funding a breadth of science research through our traditional response-mode funding schemes, Wellcome has invested additional resources in several “priority areas” – areas in which we want to see, lead and be accountable for change. One of the ways the priority areas differ from other Wellcome programmes is that they will not involve a dedicated research funding call, but instead drive progress across research, product development, policy and society. More information about Wellcome’s strategy and investment in priority areas can be found at <https://wellcome.ac.uk/about-us/our-strategy>

One of Wellcome’s priority areas is Vaccines. Vaccines prevent disease, saving lives, time and money. But infections like malaria and typhoid still harm and kill millions of people each year, and emerging diseases can cause deadly epidemics like Ebola. The world urgently needs better ways to develop and use vaccines. More information about the Vaccines programme can be found at <https://wellcome.ac.uk/what-we-do/our-work/vaccines>

As part of the Vaccines programme, Wellcome aims to promote the use of research evidence in country decision-making for vaccines and to support the development of expertise required to make evidence-informed recommendations. This project aims to summarize what’s currently known about approaches to country decision-making for vaccines and provide evidence to guide future investments in this area.

Wellcome recognises the importance of ensuring that countries have the expertise and evidence they need to make timely decisions on vaccine introduction and programmatic implementation. This will maximize the benefits of investments in new vaccine development and will ensure that the right evidence can be generated and utilised for maximal impact. Wellcome is working with partners to develop a strategy to support sustainable country decision-making for vaccines. To this end, Wellcome is requesting proposals for a landscape analysis and review of approaches to country decision-making for vaccines. The analysis will likely include a brief systematic review and landscape analysis, a review of various approaches to country decision-making for vaccines, and case studies of countries using evidence-informed decision-making for vaccines and the relative strengths and weaknesses of these approaches.

OBJECTIVES

- Conduct a landscape analysis of past and current donor and funder investments in country decision-making for vaccines, including stakeholder mapping and analysis
- Review approaches to country decision-making for vaccines and what interventions and programmes have been supported in the past, and the relative costs, strengths, and weaknesses of these interventions
- Review data, indicators, and measures of impact which could inform a future investment case



SCOPE OF WORK

Please use the following outline as a prototype that can be refined and amended to include any additional assessments that you believe are relevant to achieve the stated objectives

Landscape analysis

Conduct a landscape analysis of past and current donor and funder investments in country decision-making for vaccines including, but not limited to, investments in supporting National Immunisation Technical Advisory Groups. This should include stakeholder mapping of the various funders and other actors relevant to this space, and a network analysis of key players in vaccine decision-making at the national and global levels. The landscape analysis does not need to include investments made by governments (this element should be captured in the review of approaches to country decision-making, detailed below). This should include a weighted matrix or other evaluation mechanism to transparently assess the strengths and weaknesses of initiatives. Given the breadth of recent work that exists evaluating approaches to country decision-making for vaccines, we expect this piece will focus on compiling existing evidence rather than generating new evidence. However, if there are evidence gaps that could be filled through the generation of new evidence, please detail your approach to this.

The review should address the following questions, at minimum:

- Who are the key players in vaccine decision-making at both the national and global levels, and how do they interact with each other in this space?
- What initiatives have donors and funders supported in the past to further country decision-making for vaccines?
- How have funders supported National Immunisation Technical Advisory Groups?
- What have been the relative costs of these initiatives?
- What have been the relative strengths and weaknesses of these initiatives?
- What have been the overall impacts of these initiatives?
- Are there any gaps that these initiatives have not been able to fill?

Review of approaches to country decision-making

The review should detail what types of interventions and approaches have been taken to supporting country decision-making in low- and middle-income countries for vaccines (supported by donors/funders or governments). It may also be relevant to review country decision-making for preventative health interventions other than vaccines, if there are lessons that can be learned and applied. This should include a weighted matrix or other evaluation mechanism to transparently assess the strengths and weaknesses of interventions and programmes.

The review should address the following questions, at minimum:

- What are the various approaches taken by countries or regions to decision-making for vaccines?
- What are the relative strengths and weaknesses of these approaches?
- What have been the impacts of these approaches? Impacts may be financial, temporal, health-based, or other impacts, and should include consideration around what additional impacts could or should be measured



- What are the relative costs of these approaches?
- How do these compare to approaches to decision-making for other health interventions or investments?
- How do these approaches consider vaccines in relation to other types of health interventions or investments?
- What evidence (research or otherwise) is used to inform approaches to decision-making on vaccines?
- Where is this evidence from, and are there evidence gaps that impact decision-making?

METHODS

Several research methods can be employed for the project, including (but not limited to):

- Literature review
- Consultations with relevant internal and external stakeholders
- Analysis of selected case studies

Contacts at Wellcome will be available to consult as the project develops.

DELIVERABLES

The primary deliverables of the consultancy should include:

1. Written report outlining the results of the landscape and network analysis and approaches to country decision-making
2. A weighted matrix or other evaluation mechanism use to assess the strengths and weaknesses of interventions and programmes

The secondary deliverables of the consultancy may include:

3. A list of gaps in evidence that would facilitate a more accurate evaluation and recommendations for future evidence collection
4. A presentation (delivered in Microsoft PowerPoint format) summarising the key findings of the study
5. A two-page narrative or executive summary
6. A list of references
7. A list of people consulted in the course of this work
8. Short summary of key action items for the next year to increase support for evidence-informed decision-making for vaccines

TIMELINE

Please include a timeline in your proposal, including start date and completion dates for the primary deliverables. The expected duration for this project is one to three months, and the project should be completed by June 2019.



EVALUATION CRITERIA

Applications will be assessed based on:

- Expertise in evidence-informed decision-making
- Experience of working on similar projects
- Established contacts within the vaccine and evidence-informed decision-making space
- Expeditious timeline
- Value for money

RESPONDING TO THIS REQUEST FOR PROPOSAL

Interested parties who wish to respond to this request should submit an application using the attached template set out in Appendix 3. We anticipate that there will be some co-development of the final proposal.



Appendix 2

Wellcome General Terms and Conditions

1. **APPLICATION AND INTERPRETATION OF GENERAL TERMS AND CONDITIONS**
- 1.1 **These General Terms and Conditions shall apply to any contract or agreement to which they are stated to apply, including the Agreement. They shall apply to the entire exclusion of all other terms and conditions except those which are expressly referred to in the Agreement.**
- 1.2 **Any terms or conditions contained in the Supplier's quotation, acknowledgment or acceptance of order, specification or proposed by the Supplier in any other way shall not form part of the Agreement and the Supplier agrees that it shall not rely on such terms and conditions.**
- 1.3 In these General Terms and Conditions, references to any statute or statutory provision shall, unless the context otherwise requires, be construed as a reference to that statute or provision as from time to time amended, consolidated, extended, re-enacted or replaced, and shall include all subordinate legislation made under that statute or statutory provision. The headings in these General Terms and Conditions do not affect their interpretation.
- 1.4 The Agreement shall be read and interpreted according to the following descending order of priority: (i) the Order (ii) any Supplementary Terms and Conditions (iii) the General Terms and Conditions.
2. **COMMENCEMENT AND DURATION**
- The Agreement shall commence on the date when it has been entered into by both Parties (**Commencement Date**) and shall continue, unless terminated earlier in accordance with Clause 14, until both Parties have discharged their obligations under the Agreement when it shall terminate automatically without notice.
3. **PERFORMANCE**
- 3.1 Any services supplied under the Agreement shall: (i) be carried out with reasonable skill, care and diligence and otherwise in accordance with the standards reasonably to be expected of a competent service provider and best industry practice by appropriately skilled and qualified personnel; (ii) be carried out by the personnel stated in the Order (where applicable); (iii) be carried out at the times and on the dates (where applicable) and within the time frame specified in the Agreement; and (iv) conform to the description, specification and any other particulars stated in the Agreement.
- 3.2 Any goods supplied under the Agreement shall: (i) conform to the description, specification and quantity stated in the Agreement; (ii) comply with all statutory requirements that are in force at the time of delivery of the goods; and (iii) be delivered in accordance with the requirements for delivery set out in the Order.
- 3.3 If the Deliverables are not delivered on the due date then, without prejudice to any other rights which it may have, Wellcome may:
 - i) agree to delivery of the Deliverables on an alternative delivery date;
 - ii) cancel the Order in whole or in part;
 - iii) refuse to accept any subsequent delivery, or further performance or execution of the Deliverables which the Supplier attempts to make;
 - iv) recover from the Supplier any expenditure reasonably incurred by Wellcome in obtaining deliverables in substitution from another supplier;
 - v) claim damages for any reasonable additional costs, loss or expenses incurred by Wellcome which are in any way attributable to the Supplier's failure to deliver, execute or perform the Deliverables on the due date.
4. **RISK, PROPERTY, ACCEPTANCE AND REJECTION**
- 4.1 Risk in any Deliverables that are goods shall, without prejudice to any other rights or remedies of Wellcome, pass to Wellcome at the time of acceptance of the delivery of the goods at Wellcome. Title shall pass to Wellcome upon payment in full of the Charges.
- 4.2 Wellcome shall not be taken to have accepted any Deliverables until it has had ten (10) Business Days after delivery to inspect them. During this period and without prejudice to any other rights Wellcome may have under the Agreement, any goods supplied under the Agreement that are damaged or have suffered damage during manufacture which could not reasonably be discerned from inspection on delivery, or which are otherwise not in accordance with the Agreement, shall be returnable to the Supplier, whereupon Wellcome shall have the option to either accept a replacement or terminate the Agreement in accordance with Clause 14.1 i).
- 4.3 Following the period stated in Clause 4.2, and without prejudice to any other rights Wellcome may have under the Agreement, where any Deliverables fail to conform to the description and/or specification stated in the Agreement, or are otherwise in breach of the Agreement, Wellcome may by written notice to the Supplier reject all or any of the Deliverables and the Supplier shall at Wellcome's option either repair or replace Deliverables that are goods or rectify Deliverables that are services or works rejected by Wellcome with goods, services or works (as the case may be) which in all material respects conform to the Agreement, or otherwise promptly credit Wellcome with the invoiced price of the non-confirming Deliverables.
5. **PRICE AND PAYMENT**
- 5.1 The Charges shall remain firm for the duration of the Agreement.
- 5.2 On completion of delivery of the Deliverables or as otherwise set out in the Order, the Supplier shall invoice Wellcome for the Charges. Wellcome shall pay the Supplier the total amount of Value Added Tax (VAT) properly chargeable on the supply of the Deliverables upon receipt of a tax invoice in accordance with Regulations 13-14 of the VAT Regulations 1995.
- 5.3 If the invoice is one which, under the Agreement, the Supplier was entitled to submit and it is a valid and correct invoice and the Deliverables have been provided to the satisfaction of Wellcome, the final date for payment of an invoice by Wellcome shall be twenty (20) Business Days from receipt by Wellcome of that invoice.
- 5.4 If a Party fails to make any payment due to the other Party under this Agreement by the due date for payment, then without limiting the other Party's remedies, the defaulting Party shall pay interest on the overdue amount at the rate of 4% per annum above the Bank of England's base rate from time to time. Such interest shall accrue on a daily basis from the due date until actual payment of the overdue amount, whether before or after judgment. The defaulting Party shall pay the interest together with the overdue amount.
6. **RIGHTS OF SET-OFF**
- Wellcome may set off against, or deduct from, any payment due by Wellcome to the Supplier any sums that the Supplier owes to Wellcome.
7. **DATA PROTECTION**
- 7.1 Each Party shall, and shall procure that its personnel, comply with any notification requirements under the Data Protection Act 1998 (**DPA**) and both Parties will observe all their obligations under the DPA which arise in connection with the Agreement.
- 7.2 Where either Party is processing Personal Data (as defined in the DPA) which is provided by or on behalf of the other Party, the processing Party shall only process such data for the purposes of the Agreement and shall implement appropriate technical, organisational and contractual measures to protect against: (i) unauthorised or unlawful processing of the Personal Data; and (ii) accidental loss or destruction of, or damage to, the Personal Data, as required under the DPA's Seventh Data Protection Principle. Each Party shall promptly notify the other of any breach of this Clause 7 or any request or complaint it receives relating to the other Party's Personal Data.
- 7.3 The Supplier shall permit Wellcome to carry out checks on the Supplier's information security arrangements on reasonable notice and shall provide such information as Wellcome may at any time reasonably request to confirm that the Supplier is in compliance with the DPA.
8. **CONFIDENTIALITY**
- 8.1 Each Party undertakes that it shall not at any time during the Agreement, and for a period of two (2) years after termination of the Agreement, disclose to any person any Confidential Information of the other Party or of any member of the group of companies to which the other Party belongs, except as permitted by Clause 8.2.
- 8.2 Each Party may disclose the other Party's Confidential Information: (i) to its employees, officers, representatives or advisers who need to know such information for the purposes of carrying out the Party's obligations under the Agreement. Each Party shall procure that its employees, officers, representatives or advisers to whom it discloses the other Party's Confidential Information comply with this Clause 8; and (ii) as may be required by law, a court of competent jurisdiction or any governmental or regulatory authority; and (iii) with the prior written consent of the other Party.



- 8.3 Neither Party shall use the other Party's Confidential Information for any purpose other than to perform its obligations under the Agreement.
9. **INTELLECTUAL PROPERTY**
- 9.1 The Background Intellectual Property belonging to each Party shall remain vested in the Party owning it.
- 9.2 Each Party shall grant, or shall use reasonable endeavours to procure the grant of, all such licences to the other Party to use its Background Intellectual Property as are necessary to allow that other Party to use the Foreground Intellectual Property.
- 9.3 All Foreground Intellectual Property shall become the property of Wellcome on its creation and the Supplier irrevocably assigns, and shall procure the assignment of, any existing and future Foreground Intellectual Property Rights to Wellcome with full title guarantee and free from third party rights or encumbrances. The Supplier waives any and all of its moral rights in relation to the Foreground Intellectual Property.
- 9.4 Wellcome grants a licence to the Supplier to use the Foreground Intellectual Property free of charge and royalty and on a non-exclusive, worldwide basis to the extent necessary for the Supplier to perform its obligations or exercise its rights under the Agreement. The licence granted under this Clause 9.4 will automatically terminate on the termination or expiry of the Agreement.
- 9.5 Neither Party shall use the name, logo, trademarks or other brand collateral of the other Party without the owning Party's prior written consent.
- 9.6 The Supplier warrants and undertakes to Wellcome that:
- the manufacture, creation, supply and use of the Deliverables will not in any way constitute an infringement or other violation of any IP Rights of any third party;
 - it owns or has obtained valid licences of all IP Rights which are necessary to the performance of any of its obligations under the Agreement;
 - the IP Rights in the Deliverables created by the Supplier are and will be original and have not and will not be licensed or assigned to any third party, save as requested or approved by Wellcome in writing; and
 - it shall assign or grant a licence to use, as the case may be, to Wellcome upon request, all such rights as it may have under any third party agreement (where applicable) as may be necessary for Wellcome's use of the Deliverables.
10. **INDEMNITY**
- Unless otherwise stated in the Order, the Supplier shall indemnify, keep indemnified and hold harmless, Wellcome in respect of any and all damages, costs, claims, liabilities, expenses, losses (excluding indirect or consequential loss) and demands incurred by Wellcome, as a result of the Supplier's breach of Clause 9.6 i) of this Agreement or as a result of personal injury or death caused by the Supplier's negligence.
11. **INSURANCE**
- The Supplier warrants and undertakes to Wellcome that it has obtained and shall maintain in force for the term of the Agreement and for the period of 12 months after its termination, all relevant policies of insurance necessary or prudent for it to obtain in providing the Deliverables. The Supplier shall provide Wellcome with evidence of such policies of insurance on reasonable request.
12. **SUPPORTING INFORMATION**
- Wellcome (and its authorised representatives) may request copies of the Supplier's records relevant to this Agreement at any time on reasonable prior written notice for purposes of assessing the Supplier's performance under the Agreement.
13. **HEALTH, SAFETY AND ENVIRONMENT**
- When on Wellcome premises, the Supplier agrees to comply with Wellcome's health and safety and environment policies and associated guidance including Wellcome Health, Safety and Environment: Information and Guidelines for Contractors, which shall be provided by Wellcome, where applicable.
14. **TERMINATION**
- 14.1 Without affecting any other right or remedy available to the Parties, the Agreement may be terminated with immediate effect:
- by either Party on written notice to the other Party where the other Party commits a breach of warranty or any other material breach of any term of the Agreement and (if such breach is remediable) fails to remedy that breach within twenty (20) Business Days of being notified to do so;
 - by Wellcome on written notice to the Supplier where the Supplier repeatedly breaches any of the terms of the Agreement in a way that reasonably suggests it has no intention of giving effect to the terms of the Agreement;
 - by Wellcome on written notice to the Supplier where the Supplier (a) suspends or ceases, or threatens to suspend or cease, carrying on all or a substantial part of its business; (b) is unable to pay its debts as they fall due; (c) enters liquidation or winding up except for the purpose of a bona fide merger acquisition, reconstruction or amalgamation; or (d) circumstances arise which entitle a court or a creditor to appoint a receiver, a manager or administrator over the Supplier or over any or all of the Supplier's business or which entitle a court to make a winding-up order (except for the purpose of a bona fide merger, acquisition, reconstruction or amalgamation).
- 14.2 Without affecting any other right or remedy available to it, Wellcome may terminate the Agreement for convenience on giving not less than ten (10) Business Days' written notice to the Supplier provided that Wellcome shall pay the Supplier for all Deliverables delivered or completed in accordance with the Agreement (but not already paid for) at the termination date; or if not due to be delivered or completed at the termination date, a fair and reasonable sum in respect of the progress made by the Supplier on the Deliverables as at the termination date.
15. **CONSEQUENCES OF TERMINATION**
- 15.1 On termination of the Agreement:
- the Supplier shall immediately cease all work and return all Wellcome property, including all Wellcome Data which the Supplier shall (at Wellcome's option) either return or delete;
 - Wellcome may reject all or any part of the Deliverables and where possible return them to the Supplier at the risk and cost of the Supplier on the basis that a full refund for the Deliverables so returned shall be paid forthwith by the Supplier; and
 - the Supplier shall within twenty (20) Business Days of the date of termination refund to Wellcome all prepaid Charges for Deliverables yet to be provided under the Order.
- 15.2 On termination or expiry of the Agreement Clauses 7, 8, 9, 10, 11, 14.2, 15, 16 and Clauses 19-24 inclusive shall continue in force.
16. **APPLICABLE LAW AND POLICY**
- In obtaining the Agreement, the Supplier warrants that neither it nor any Supplier personnel has done, and in performing its obligations under the Agreement, shall not do, any act or thing that contravenes any Wellcome policy, standards or guidelines or any applicable laws and/or regulations, including but not limited to the Bribery Act 2010.
17. **FORCE MAJEURE**
- Neither Party shall be in breach of the Agreement nor liable for delay in performing, or failure to perform, any of its obligations under the Agreement if such delay or failure results from a Force Majeure Event. In such circumstances the affected Party shall be entitled to a reasonable extension of the time for performing such obligations. If the period of delay or non-performance continues for ten (10) Business Days, the Party not affected may terminate the Agreement by giving five (5) Business Days written notice to the affected Party.
18. **ASSIGNMENT AND OTHER DEALINGS**
- 18.1 The Supplier shall not assign, transfer, sub-contract or similarly deal with any of its rights and obligations under the Agreement without Wellcome's prior written consent (which Wellcome may withhold in its absolute discretion).
- 18.2 If the Supplier is permitted to assign or subcontract any of its obligations under the Agreement the assignment or subcontract shall not relieve the Supplier of its obligations to Wellcome under the Agreement.
- 18.3 Wellcome may assign or transfer any of its rights or obligations under the Agreement to another company within the Wellcome group and may subcontract any of its rights or obligations under the Agreement.
19. **ANNOUNCEMENTS AND PUBLICITY**
- Unless otherwise provided for in this Agreement, the Supplier shall not make, or permit any person to make, any public announcement concerning the Agreement or the Deliverables without the prior written consent of Wellcome.



20. NOTICES

- 20.1 Any notice given to a Party under or in connection with the Agreement shall be in writing addressed to the Party representative named in the Order and shall be delivered by hand or by pre-paid first-class post or other next working day delivery service at its registered office or its principal place of business (where the organisation is not a limited company), or sent by email including text in the subject line of the e-mail identifying the contents of the email as a formal notice given under the Agreement. Notice of any proceedings or other documents in any legal action may not be served by way of email.
- 20.2 The contact names and addresses for service of a notice (which may be amended by notice from time to time) are set out in the Order.
- 20.3 Any notice shall be deemed to have been received (i) if delivered by hand, on signature of a delivery receipt or (ii) if sent by pre-paid first-class post or other next working day delivery service, at 9.00 am on the second Business Day after posting or (iii) if sent by email, on the Business Day of sending the notice to the correct email address (as provided by the intended recipient Party) if sent between 09.00 and 17.00 on a Business Day or on the following Business day if sent after 17.00.

21. ENTIRE AGREEMENT

- 21.1 The Agreement constitutes the entire agreement between the Parties and supersedes and extinguishes all previous agreements, promises, assurances, warranties, representations and understandings between them, whether written or oral, relating to its subject matter.
- 21.2 Each Party acknowledges to the other that it has not been induced to enter into this Agreement by any representation, warranty or undertaking by or on behalf of the other Party or any other person save for those contained in the Agreement.

22. GENERAL

- 22.1 No variation of the Agreement shall be effective unless it is in writing and signed by the Parties' authorised representatives.
- 22.2 No failure or delay by a Party to exercise any right or remedy provided under the Agreement or by law shall constitute a waiver

of that or any other right or remedy, nor shall it prevent or restrict the further exercise of that or any other right or remedy.

- 22.3 If any provision or part-provision of the Agreement is or becomes invalid, illegal or unenforceable, it shall be deemed modified to the minimum extent necessary to make it valid, legal and enforceable. If such modification is not possible, the relevant provision or part-provision shall be deemed deleted. Any modification to or deletion of a provision or part-provision under this Clause shall not affect the validity and enforceability of the rest of the Agreement.
- 22.4 Each right or remedy of Wellcome under the Agreement is in addition and without prejudice to any other right or remedy of Wellcome, whether under the Agreement or at common law or under statute, and in no way limits these other rights.
- 22.5 Nothing in the Agreement is intended to, or shall be deemed to, establish any partnership or joint venture between the Parties, constitute any Party the agent, worker or employee of another Party, or authorise any Party to make or enter into any commitments for or on behalf of any other Party and neither Party shall hold itself out as such.
- 22.6 No term of the Agreement may be enforced by a third party solely by virtue of the Contracts (Rights of Third Parties) Act 1999.

23. DISPUTE RESOLUTION

The Parties shall attempt in good faith to resolve any dispute arising out of this Agreement, within ten (10) Business Days of a Party giving notice of such a dispute to the other Party, through negotiations between the Parties' representatives as referred to in the Order. If the dispute is not resolved within that time, the dispute shall be referred to a more senior officer from each Party who shall have a further ten (10) Business Days within which to resolve the dispute. If the dispute still remains unresolved ten (10) Business Days after referral to senior officers, the dispute shall be resolved in accordance with Clause 24.

24. GOVERNING LAW AND JURISDICTION

The construction, validity and performance of this Agreement shall be exclusively governed by the laws of England and Wales and the Parties submit to the exclusive jurisdiction of the Courts of England and Wales.

DEFINITIONS

Agreement: together, these General Terms and Conditions, an Order, any amendments to these General Terms and Conditions and any Supplementary Conditions set out in the relevant Order, and any annexes attached to the relevant Order.

Background Intellectual Property: any Intellectual Property, other than Foreground Intellectual Property, owned by a Party or over which a Party has rights, which is expressly made available by Wellcome or the Supplier under the Agreement.

Business Day: a day other than a Saturday, Sunday or public holiday in England when banks in London are closed for business, excluding days nominated by Wellcome on reasonable notice for planned closure of its offices.

Charges: the charges for the Deliverables set out in the Order.

Confidential Information: the content of the Agreement and any information, including Wellcome Data, in whatever form (including in written, oral, visual or electronic form or on any magnetic or optical disk or memory and wherever located) relating to the business, suppliers, products, affairs and finances, business proposals of either Party for the time being confidential to a Party and trade secrets or commercially-sensitive information including technical data and know-how relating to a Party's business or any of their suppliers, customers, agents, distributors, shareholders, management or business contacts and including information that the Supplier creates, develops, receives or obtains in connection with the Agreement, whether or not such information (if in anything other than oral form) is marked confidential.

Deliverables: the goods and/or services to be supplied, or the work(s) to be undertaken, by the Supplier described in the Order, as applicable.

Force Majeure Event: any circumstances beyond the reasonable control of either Party and which occur after the date of the Order (or, if earlier, the date on which the Supplier commenced providing the Deliverables) and whose effects are not capable of being overcome without causing unreasonable expense or loss to the Party affected. Force Majeure will include but not be limited to: war and other hostilities, riots, fire, flood, earthquake or other natural disaster or act of God, civil disturbance, terrorist activity, interruption or failure of utility service, disease epidemic or pandemic. A Force Majeure Event will not include any industrial action occurring within the Supplier's (or any sub-contractor of the Supplier) organisation.

Foreground Intellectual Property: any and all Intellectual Property arising from, made, conceived, generated, developed or first reduced to practice (in whole or in part) by Wellcome or the Supplier in connection with the Agreement.

IP Rights: patents, rights to inventions, copyright and related rights, moral rights, trademarks and service marks, business names and domain names, rights in get-up, goodwill and the right to sue for passing off, rights in designs, rights in computer software, database rights, rights to use, and protect the confidentiality of confidential information (including know-how and trade secrets) and all other intellectual property rights, in each case whether registered or unregistered and including all applications and rights to apply for and be granted, renewals or extensions of, and rights to claim priority from, such rights and all similar or equivalent rights or forms of protection which subsist or will subsist now or in the future in any part of the world and the term "Intellectual Property" shall be construed accordingly.

Order: either the Order for Procurement of Deliverables or the purchase order, as applicable.

Order for Procurement of Deliverables: any front sheet to these General Terms and Conditions entitled "Order for Procurement of Deliverables".

Party: either of Wellcome and the Supplier and in the plural both of them.

Supplementary Terms and Conditions: means any supplementary terms and conditions referred to in the Order.

Supplier: means the organisation, firm or company named as the Supplier in the Order who is to supply the Deliverables to Wellcome

Wellcome Data: means any and all data in any format (including Personal Data) which is provided by or on behalf of Wellcome to the Supplier or which is made available to the Supplier or to which the Supplier obtains access in the course of providing the Deliverables.

Wellcome: The Wellcome Trust Limited, a company registered in England and Wales (no. 2711000), as trustee of the Wellcome Trust, a charity registered in England and Wales (no. 210183), whose registered office is at Gibbs Building, 215 Euston Road, London NW1 2BE, UK.



Appendix 3 – Response template

Question	Response
Section 1: Contact Information	
Please provide contact details for the main point of contact for this piece of consultancy.	
Name of company:	
Named contact:	
Position:	
Address:	
email:	
Telephone:	
Section 2: Relevant experience and skills	
Provide a summary of your skills and experience that demonstrate your organisation's ability to undertake the research outlined in the <i>Specification</i> . Please give examples of any similar studies you have conducted. Please provide two relevant references,	
Response:	
Section 3: Approach	
Provide an outline of the approach you would undertake to answer the questions outlined in the <i>Specification</i> , including a consultation plan.	
Response:	
Section 4: People	
Provide a short summary of the people who would be assigned to this project and their key skills, including CVs.	
Response:	

